Novo Nordisk Announces Phase 3a Results Using Emisphere’s Technology  


Novo Nordisk recently announced the completion and results regarding its Pioneer 9 and Pioneer 6 Phase 3a trials, both conducted with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog. Both studies utilized Emisphere Technologies, Inc.’s proprietary Eligen SNAC Carrier Technology. These two clinical trials represent the completion of Novo Nordisk’s 10-study Pioneer Phase 3a oral semaglutide clinical program.

A copy of the detailed Novo Nordisk’s study announcements on the Pioneer 9 and Pioneer 6 studies can be viewed at the following respective links:

  1. https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2226789.html
  2. https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2226662.html

Emisphere is a drug delivery company that utilizes its proprietary Eligen Technology to develop new oral formulations of therapeutic agents. Emisphere is currently partners with global pharmaceutical companies for the development of new orally delivered therapeutics. For more information, visit www.emisphere.com.

Share This